MXPA04009929A - Tratamiento de la gastroparesis. - Google Patents

Tratamiento de la gastroparesis.

Info

Publication number
MXPA04009929A
MXPA04009929A MXPA04009929A MXPA04009929A MXPA04009929A MX PA04009929 A MXPA04009929 A MX PA04009929A MX PA04009929 A MXPA04009929 A MX PA04009929A MX PA04009929 A MXPA04009929 A MX PA04009929A MX PA04009929 A MXPA04009929 A MX PA04009929A
Authority
MX
Mexico
Prior art keywords
gastroparesis
treatment
glp
patients
compounds
Prior art date
Application number
MXPA04009929A
Other languages
English (en)
Spanish (es)
Inventor
Thurman Dwight Mckinney
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MXPA04009929A publication Critical patent/MXPA04009929A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
MXPA04009929A 2002-04-10 2003-03-27 Tratamiento de la gastroparesis. MXPA04009929A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37165002P 2002-04-10 2002-04-10
PCT/US2003/008457 WO2003087139A2 (en) 2002-04-10 2003-03-27 Treatment of gastroparesis

Publications (1)

Publication Number Publication Date
MXPA04009929A true MXPA04009929A (es) 2006-03-10

Family

ID=29250714

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04009929A MXPA04009929A (es) 2002-04-10 2003-03-27 Tratamiento de la gastroparesis.

Country Status (18)

Country Link
US (1) US20050164925A1 (enExample)
EP (1) EP1496924A4 (enExample)
JP (1) JP2005530732A (enExample)
KR (1) KR20040098063A (enExample)
CN (1) CN1735423A (enExample)
AU (1) AU2003220403A1 (enExample)
BR (1) BR0308904A (enExample)
CA (1) CA2480858A1 (enExample)
EA (1) EA200401345A1 (enExample)
EC (1) ECSP045345A (enExample)
HR (1) HRP20040939A2 (enExample)
IL (1) IL164266A0 (enExample)
MX (1) MXPA04009929A (enExample)
NO (1) NO20044815L (enExample)
NZ (1) NZ535684A (enExample)
PL (1) PL373658A1 (enExample)
WO (1) WO2003087139A2 (enExample)
ZA (1) ZA200408111B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
US8666495B2 (en) 1999-03-05 2014-03-04 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US8792985B2 (en) 2003-07-21 2014-07-29 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
TW200526254A (en) * 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
EP1667724A2 (en) * 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
EP1793891B1 (en) 2004-08-18 2011-11-09 Metacure Limited Monitoring, analysis, and regulation of eating habits
US9821158B2 (en) 2005-02-17 2017-11-21 Metacure Limited Non-immediate effects of therapy
US9339190B2 (en) 2005-02-17 2016-05-17 Metacure Limited Charger with data transfer capabilities
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
MX2007011307A (es) 2005-03-18 2007-10-08 Novo Nordisk As Compuestos de glp-1 extendidos.
EP1861160B1 (en) * 2005-03-24 2011-11-16 Metacure Limited Wireless leads for gastrointestinal tract applications
US8463404B2 (en) 2005-03-24 2013-06-11 Metacure Limited Electrode assemblies, tools, and methods for gastric wall implantation
US8301256B2 (en) 2005-06-02 2012-10-30 Metacure Limited GI lead implantation
US8442841B2 (en) * 2005-10-20 2013-05-14 Matacure N.V. Patient selection method for assisting weight loss
US8295932B2 (en) 2005-12-05 2012-10-23 Metacure Limited Ingestible capsule for appetite regulation
AU2012203915B9 (en) * 2006-04-20 2014-10-09 Amgen Inc. GLP-1 compounds
AU2007240313B2 (en) * 2006-04-20 2012-02-02 Amgen Inc. GLP-1 compounds
EP2150308B1 (en) * 2007-05-09 2018-08-08 MetaCure Limited Analysis and regulation of food intake
US8423130B2 (en) * 2008-05-09 2013-04-16 Metacure Limited Optimization of thresholds for eating detection
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
CN102292349B (zh) 2009-01-22 2016-04-13 诺沃—诺迪斯克保健股份有限公司 稳定的生长激素化合物
CN102612376A (zh) 2009-08-06 2012-07-25 诺沃-诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
US8642548B2 (en) * 2009-08-07 2014-02-04 Mannkind Corporation Val (8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
MX345736B (es) 2010-01-22 2017-02-14 Novo Nordisk Healthcare Ag Hormonas de crecimiento con eficacia in vivo prolongada.
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
WO2011092710A2 (en) * 2010-02-01 2011-08-04 Metacure Limited Gastrointestinal electrical therapy
AU2011245980A1 (en) 2010-04-30 2012-11-08 Sanwa Kagaku Kenkyusho Co., Ltd. Peptide for improving in vivo stability of physiologically active substance or the like and physiologically active substance with improved in vivo stability
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
PT2934568T (pt) 2012-12-21 2018-01-04 Sanofi Sa Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina
CN105120887A (zh) 2013-04-05 2015-12-02 诺和诺德保健股份有限公司 生长激素化合物制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US5981488A (en) * 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand

Also Published As

Publication number Publication date
JP2005530732A (ja) 2005-10-13
CN1735423A (zh) 2006-02-15
EA200401345A1 (ru) 2005-08-25
PL373658A1 (en) 2005-09-05
ECSP045345A (es) 2006-04-19
NZ535684A (en) 2006-03-31
AU2003220403A1 (en) 2003-10-27
EP1496924A4 (en) 2007-05-30
US20050164925A1 (en) 2005-07-28
IL164266A0 (en) 2005-12-18
ZA200408111B (en) 2005-10-07
WO2003087139A3 (en) 2004-01-08
EP1496924A2 (en) 2005-01-19
KR20040098063A (ko) 2004-11-18
NO20044815L (no) 2005-01-07
BR0308904A (pt) 2005-05-03
CA2480858A1 (en) 2003-10-23
HRP20040939A2 (en) 2004-12-31
WO2003087139A2 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
MXPA04009929A (es) Tratamiento de la gastroparesis.
TW200505434A (en) Therapeutic treatment
AU2003300791A1 (en) Combination therapy for the treatment of pain
WO2006113802A3 (en) Device for administering electrode stimulation of back and abdominal muscles
GB0216321D0 (en) Therapeutic treatment
EP1572095A4 (en) S-L-2 DESOXYNUCLEOSIDE FOR THE TREATMENT OF RESISTANT HBV-STRAINS AND COMBINATION THERAPIES
EP1404343A4 (en) THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF HORMONE DEFICIENCIES
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
MXPA04004306A (es) Uso de antagonistas del receptor de endotelina para el tratamiento de enfermedades tumorales.
WO2004004653A3 (en) Methods for treating psychosis associated with interferon-alpha therapy
EP1401268A4 (en) TREATMENT OR SPARE THERAPY WITH TRANSGENIC STEM CELLS DELIVERED TO THE DARM
IL158738A0 (en) Novel use of 2-phenyl-substituted imidazotriazinones
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
GB0213869D0 (en) The treatment of pain
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
IL178827A0 (en) Use of reboxetine for the treatment of pain
PT1670489E (pt) Utilização de xénon com hipotermia para o tratamento de asfixia neonatal
GB0223854D0 (en) Therapeutic treatment
PT1603584E (pt) Aplidina para o tratamento de mieloma múltiplo
LT1496918T (lt) Natrio meta-arsenito naudojimas navikams gydyti
PT1530462E (pt) Compostos 1-fenil-2-dimetilaminometilciclo-hexano utilizados na terapia dos sintomas depressivos, dor e incontinência
MXPA03006742A (es) Uso de buprenorfina para la terapia de la incontinencia urinaria.
MXPA05012605A (es) Composiciones que comprenden compuestos de gastrina y sus usos en la diabetes.
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases

Legal Events

Date Code Title Description
FA Abandonment or withdrawal